share_log

Bull Horn Holdings Corp. Combination Partner Coeptis Therapeutics Enters Into Exclusive Option Agreement With University Of Pittsburgh For Rights To CAR-T Technologies Designed To Target Multiple Cancer Indications, Including Hematologic And Solid Tumors

Bull Horn Holdings Corp. Combination Partner Coeptis Therapeutics Enters Into Exclusive Option Agreement With University Of Pittsburgh For Rights To CAR-T Technologies Designed To Target Multiple Cancer Indications, Including Hematologic And Solid Tumors

牛角控股公司聯合合作夥伴 Coeptis 治療學與匹茲堡大學簽訂獨家期權協議,獲得旨在針對多種癌症適應症(包括血液學和實體腫瘤)的 CAR-T 技術的權利
Benzinga Real-time News ·  2022/05/17 07:21
Option agreement comprises three technologies and associated patent portfolios
期權協議包括三種技術和相關專利組合
Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative cell therapy platforms
該公告標誌著 Coeptis 本季度第三份戰略協議旨在增強其產品組合並補充其創新的細胞治療平台
WEXFORD, Pa., May 17, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors. Among the initial cancer indications under development...
威克斯福德,賓夕法尼亞州威克斯福德,2022 年 5 月 17 日/新聞通訊/-科普斯治療有限公司(OTC:COEP)(「Coeptis」...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論